51 completed, 25 unknown, 12 recruiting, 2 terminated. 31 Phase 2, 27 Not applicable, 9 Phase 1, 7 Phase 4, 5 Phase 3.
Follow Hospital Universitario Dr. Jose E. Gonzalez: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The FILTRATE Trial: High-Rate Ultrafiltration for Intravascular Congestion High-rate ultrafiltration, Standard fluid removal - End Stage Chronic Renal Failure, Congestive Heart Failure (CHF) | Not applicable | Recruiting | Universidad Autonoma de Nuevo Leon | 70 | 2026-06-04 | 2026-07-15 |
| Low Dose Epcoritamab Plus GemOx in R/R DLBCL Epcoritamab, Gemcitabine (1000 mg/m2), Oxaliplatin - Relapsed/Refractory Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 10 | 2026-03-17 | 2026-04-01 |
| Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis Semaglutide (Rybelsus®), Placebo - Psoriasis (PsO), Obesity & Overweight | Phase 4 | Recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 62 | 2026-01-15 | 2026-02-11 |
| Anti-Inflammatory Effects of Pecan Nut Oil Supplementation in Adults With Overweight: A Randomized Controlled Parallel-Group Clinical Trial Pecan nut oil supplementation - Overweight (BMI > 25) | Not applicable | Recruiting | Universidad Autonoma de Nuevo Leon | 50 | 2025-10-15 | 2026-03-27 |
| Probiotic and Prebiotic Supplementation in Peritoneal Dialysis Patients Synbiotic, Placebo - Chronic Kidney Disease (Stages 4 and 5), Peritoneal Dialysis (PD) | Not applicable | Recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 60 | 2025-10-03 | 2026-07-10 |
| Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients Low-dose teclistamab - Multiple Myeloma, Newly Diagnosed | Phase 2 | Recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 10 | 2025-03-03 | 2025-03-20 |
| The Safety and Microbial Changes in the Use of Intranasal Neosporin® Intranasal application of Polymyxin B Sulfate 500,000 IU, Bacitracin zinc 40,000 IU, Neomycin Sulfate 0.35g neomycin base - Teste the Safety of (Polymyxin B Sulfate 500,000 IU, Bacitracin Zinc 40,000 IU, Neomycin Sulfate 0.35g Neomycin Base) Intranasally | Not applicable | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 12 | 2025-02-13 | 2026-07-14 |
| Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment Human chorionic gonadotropin (hCG), Prednisone, Dexamethasone - Acute Graft Versus Host Disease | Phase 2 | Recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 20 | 2025-02-01 | 2025-04-03 |
| Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients Venetoclax low dose with itraconazole - Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent | Phase 2 | Recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 12 | 2025-01-02 | 2025-10-02 |
| Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL Short course of blinatumomab - Acute Lymphoblastic Leukemia, Measurable Residual Disease (MRD) | Phase 2 | Recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2025-01-02 | 2025-03-20 |
| Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia Dasatinib Pill, Ketoconazole Pill - Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 15 | 2024-11-01 | 2022-12-06 |
| Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation total marrow and total lymphoid irradiation - Acute Lymphoblastic Leukemia | Not applicable | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 14 | 2023-09-01 | 2026-03-25 |
| Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT Cyclosporine ophthalmic solution 0.1%, Tacrolimus ophthalmic ointment 0.03% - Ocular Graft-versus-host Disease | Phase 1 / Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 60 | 2023-08-01 | 2024-04-08 |
| Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma low dose nivolumab in combination with AVD - Safety Issues, Efficacy, Self | Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 16 | 2023-02-13 | 2023-03-16 |
| Implementation of an Outpatient Parenteral Antimicrobial Therapy Program Place of treatment - Outpatient | Not applicable | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 40 | 2023-02-01 | 2023-02-01 |
| Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT Cyclophosphamide - Graft Versus Host Disease | Phase 2 | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 35 | 2023-01-01 | 2026-01-06 |
| Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke Cerebrolysin, Brain-MRI with contrast after 10-14 days of cerebrolysin - Ischemic Stroke, Acute, Diabetes Mellitus, Type 2 | Phase 4 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 60 | 2022-11-17 | 2024-02-22 |
| Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL Arsenic trioxide, all-trans retinoic acid - Promyelocytic Leukemia | Phase 1 / Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 15 | 2022-07-01 | 2022-10-26 |
| Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant Pegfilgrastim - Myeloma Multiple, Lymphoma | Phase 2 | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2022-04-01 | 2023-02-28 |
| Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease Low-dose ibrutinib - Chronic Graft-versus-host-disease | Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 13 | 2022-04-01 | 2022-04-27 |
Showing 20 of 93. Sign in to see all of them.
COVID-19 (6) · Purpura, Thrombocytopenic, Idiopathic (4) · Renal Insufficiency, Chronic (4) · Cerebral Palsy (3) · Coronavirus Infections (3) · Cytokine Release Syndrome (3) · Diabetes Mellitus (3) · Diabetes Mellitus, Type 2 (3) · Graft vs Host Disease (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Bronchiolitis Obliterans Syndrome (2) · Dry Eye Syndromes (2) · Hodgkin Disease (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Acute (2)
Rituximab (5) · Dexamethasone (4) · Alemtuzumab (3) · Acetaminophen (2) · Cyclosporine (2) · Dasatinib (2) · Folic Acid (2) · Itraconazole (2) · Observation (2) · cerebrolysin (2) · eltrombopag (2) · venetoclax (2) · Anti-Inflammatory Agents, Non-Steroidal (1) · Arsenic Trioxide (1) · Azacitidine (1)
Mexico (87)
David Gomez-Almaguer, MD (4) · Karim Mohamed-Noriega, M.D. (3) · Adrian Camacho-Ortiz, MD (2) · Consuelo Mancias-Guerra, MD (2) · Fernando J Lavalle, MD (2) · Adrian B Cuellar-Barboza, MD (1) · Adrian Camacho Ortiz, MD (1) · Adrian Camacho Ortiz, MD, PhD (1) · Adrian Camacho-Ortiz, PhD (1) · Alma R Marroquin-Escamilla, MD (1)
PMID 24802773, PMID 31618456, PMID 10368193, PMID 10737279, PMID 11328918, PMID 11722682, PMID 14616423, PMID 15880129, PMID 15908987, PMID 17631348, PMID 18353396, PMID 19720922, PMID 19766136, PMID 20067838, PMID 20530974, PMID 2056576, PMID 20840327, PMID 20841509, PMID 20934693, PMID 21300401, PMID 21464263, PMID 21518322, PMID 21999374, PMID 22133770, PMID 22163120, PMID 22650964, PMID 23303886, PMID 23350735, PMID 23470153, PMID 23602223, PMID 23697526, PMID 24576054, PMID 24642016, PMID 25208303, PMID 25456364, PMID 25498356, PMID 25584995, PMID 25830126, PMID 25918915, PMID 26534874, PMID 26709028, PMID 26871197, PMID 27318038, PMID 27633632, PMID 27913562, PMID 28067870, PMID 28360040, PMID 28410767, PMID 28434018, PMID 28673610